ALS Investment Fund is a venture capital firm in Amsterdam that focuses on supporting and finances biotech companies. Founded 2016 in Amsterdam, Noord-Holland, The Netherlands, it invests in series A, series C and venture rounds. Its portfolio companies include Apic Bio, Verge Genomics, Emulate, Orphazyme, and Amylyx Pharmaceutical. As of March 2020, ALS Investment Fund has made five investments. Their most recent investment was on January 7, 2019, when Apic Bio raised $40M. ALS Investment Fund has had one exit, which was Orphazyme. Apic Bio, Inc. is a biotechnology company that advances therapies to treat rare diseases with complex mechanisms.